Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy

Objective To investigate the frequency of serum autoantibodies targeting contactin‐associated protein 1 (Caspr1) and its complexes with other paranode antigens, contactin‐1 (CNTN1) and neurofascin 155 (NF155), in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental neuroimmunology 2023-05, Vol.14 (2), p.116-121
Hauptverfasser: Koga, Michiaki, Maeda, Toshihiko, Shimizu, Fumitaka, Kanda, Takashi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 121
container_issue 2
container_start_page 116
container_title Clinical & experimental neuroimmunology
container_volume 14
creator Koga, Michiaki
Maeda, Toshihiko
Shimizu, Fumitaka
Kanda, Takashi
description Objective To investigate the frequency of serum autoantibodies targeting contactin‐associated protein 1 (Caspr1) and its complexes with other paranode antigens, contactin‐1 (CNTN1) and neurofascin 155 (NF155), in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sera from 26 CIDP patients, 35 patients with Guillain–Barré syndrome, and 31 healthy individuals participated. Paranodal immunoglobulin G antibodies were quantified using enzyme‐linked immunosorbent assays with commercially available recombinant proteins as antigens. Results Anti‐Caspr1 antibodies were present in one participant (case 1, 3.8%) of CIDP, and negative in all Guillain–Barré syndrome patients and healthy participant. Case 1 was a man who developed subacute distal limb‐predominant muscle weakness and sensory ataxia with postural hand tremor at 69 years‐of‐age, and therapeutic benefit of intravenous immunoglobulin and oral steroids was inadequate. The detected anti‐Caspr1 antibodies predominantly belonged to the immunoglobulin G4 subclass, and the addition of CNTN1 to Caspr1 as an antigen increased antibody reactivity, although the increase was just 20–30% at most. The presence of autoantibodies against paranode protein complexes, including Caspr1/CNTN1, Caspr1/NF155 and Caspr1/CNTN1/NF155, was confirmed in several CIDP patients, although they also had anti‐Caspr1 or anti‐NF155 antibodies; thus, in our cohort, there were no patients with autoantibodies that specifically recognized paranode protein complexes. Conclusions This is the first confirmed Japanese case of anti‐Caspr1 antibody‐positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. The first Japanese case of anti‐contactin‐associated protein 1 antibody‐positive chronic inflammatory demyelinating polyradiculoneuropathy showed similar clinical pictures to cases reported from Western countries, including enlargement of the nerve roots with gadolinium contrast effect.
doi_str_mv 10.1111/cen3.12735
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2815462447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2815462447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3065-7aa22e257da94d9c14bc8d0691be8c3f44b9ff44dc020131dcdf25ea9d49921d3</originalsourceid><addsrcrecordid>eNp9kc9KxDAQxosoKOrFJwh4E3Zt0nTbHGVZ_8CiFz2X2WS6m6VNapKivfkIPoLgm_goPolZV8GTc5gZht83M_AlyQlNxzTGuUSTjSkrsnwnOaBFLkZUTOjun34_OfZ-ncbIypIX_CB5v-iDBRP0wiqNnsAStPGBSGsCyKDN58sreG-lhoCKdM4G1ObjjRIwKlJt1-Bz1NmadODAWIVR4TuUutbyl_dEGyJXzpo406ZuoG0hWDcQhe2AjTYQTy1JZ5vBgdKyb6zB3tkOwmo4SvZqaDwe_9TD5OFydj-9Hs3vrm6mF_ORzNJJPioAGEOWFwoEV0JSvpClSieCLrCUWc35QtQxK5mylGZUSVWzHEEoLgSjKjtMTrd749ePPfpQrW3vTDxZsZLmfMI4LyJ1tqWks947rKvO6RbcUNG02vhQbXyovn2IMN3CT7rB4R-yms5us63mC5R1kqM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2815462447</pqid></control><display><type>article</type><title>Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy</title><source>Wiley Online Library All Journals</source><creator>Koga, Michiaki ; Maeda, Toshihiko ; Shimizu, Fumitaka ; Kanda, Takashi</creator><creatorcontrib>Koga, Michiaki ; Maeda, Toshihiko ; Shimizu, Fumitaka ; Kanda, Takashi</creatorcontrib><description>Objective To investigate the frequency of serum autoantibodies targeting contactin‐associated protein 1 (Caspr1) and its complexes with other paranode antigens, contactin‐1 (CNTN1) and neurofascin 155 (NF155), in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sera from 26 CIDP patients, 35 patients with Guillain–Barré syndrome, and 31 healthy individuals participated. Paranodal immunoglobulin G antibodies were quantified using enzyme‐linked immunosorbent assays with commercially available recombinant proteins as antigens. Results Anti‐Caspr1 antibodies were present in one participant (case 1, 3.8%) of CIDP, and negative in all Guillain–Barré syndrome patients and healthy participant. Case 1 was a man who developed subacute distal limb‐predominant muscle weakness and sensory ataxia with postural hand tremor at 69 years‐of‐age, and therapeutic benefit of intravenous immunoglobulin and oral steroids was inadequate. The detected anti‐Caspr1 antibodies predominantly belonged to the immunoglobulin G4 subclass, and the addition of CNTN1 to Caspr1 as an antigen increased antibody reactivity, although the increase was just 20–30% at most. The presence of autoantibodies against paranode protein complexes, including Caspr1/CNTN1, Caspr1/NF155 and Caspr1/CNTN1/NF155, was confirmed in several CIDP patients, although they also had anti‐Caspr1 or anti‐NF155 antibodies; thus, in our cohort, there were no patients with autoantibodies that specifically recognized paranode protein complexes. Conclusions This is the first confirmed Japanese case of anti‐Caspr1 antibody‐positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. The first Japanese case of anti‐contactin‐associated protein 1 antibody‐positive chronic inflammatory demyelinating polyradiculoneuropathy showed similar clinical pictures to cases reported from Western countries, including enlargement of the nerve roots with gadolinium contrast effect.</description><identifier>ISSN: 1759-1961</identifier><identifier>EISSN: 1759-1961</identifier><identifier>DOI: 10.1111/cen3.12735</identifier><language>eng</language><publisher>Ube: Wiley Subscription Services, Inc</publisher><subject>Antibodies ; Antigens ; Ataxia ; Autoantibodies ; chronic inflammatory demyelinating polyradiculoneuropathy ; Contactin ; contactin‐1 ; contactin‐associated protein 1 ; Demyelination ; Guillain-Barre syndrome ; Immunoglobulin G ; Immunoglobulin G4 ; Immunoglobulins ; Inflammation ; neurofascin 155 ; Proteins ; Steroid hormones ; Tremor</subject><ispartof>Clinical &amp; experimental neuroimmunology, 2023-05, Vol.14 (2), p.116-121</ispartof><rights>2022 Japanese Society for Neuroimmunology.</rights><rights>2023 Japanese Society for Neuroimmunology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3065-7aa22e257da94d9c14bc8d0691be8c3f44b9ff44dc020131dcdf25ea9d49921d3</citedby><cites>FETCH-LOGICAL-c3065-7aa22e257da94d9c14bc8d0691be8c3f44b9ff44dc020131dcdf25ea9d49921d3</cites><orcidid>0000-0003-4163-2939 ; 0000-0002-1356-955X ; 0000-0003-1049-4924</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcen3.12735$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcen3.12735$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Koga, Michiaki</creatorcontrib><creatorcontrib>Maeda, Toshihiko</creatorcontrib><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><title>Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy</title><title>Clinical &amp; experimental neuroimmunology</title><description>Objective To investigate the frequency of serum autoantibodies targeting contactin‐associated protein 1 (Caspr1) and its complexes with other paranode antigens, contactin‐1 (CNTN1) and neurofascin 155 (NF155), in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sera from 26 CIDP patients, 35 patients with Guillain–Barré syndrome, and 31 healthy individuals participated. Paranodal immunoglobulin G antibodies were quantified using enzyme‐linked immunosorbent assays with commercially available recombinant proteins as antigens. Results Anti‐Caspr1 antibodies were present in one participant (case 1, 3.8%) of CIDP, and negative in all Guillain–Barré syndrome patients and healthy participant. Case 1 was a man who developed subacute distal limb‐predominant muscle weakness and sensory ataxia with postural hand tremor at 69 years‐of‐age, and therapeutic benefit of intravenous immunoglobulin and oral steroids was inadequate. The detected anti‐Caspr1 antibodies predominantly belonged to the immunoglobulin G4 subclass, and the addition of CNTN1 to Caspr1 as an antigen increased antibody reactivity, although the increase was just 20–30% at most. The presence of autoantibodies against paranode protein complexes, including Caspr1/CNTN1, Caspr1/NF155 and Caspr1/CNTN1/NF155, was confirmed in several CIDP patients, although they also had anti‐Caspr1 or anti‐NF155 antibodies; thus, in our cohort, there were no patients with autoantibodies that specifically recognized paranode protein complexes. Conclusions This is the first confirmed Japanese case of anti‐Caspr1 antibody‐positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. The first Japanese case of anti‐contactin‐associated protein 1 antibody‐positive chronic inflammatory demyelinating polyradiculoneuropathy showed similar clinical pictures to cases reported from Western countries, including enlargement of the nerve roots with gadolinium contrast effect.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Ataxia</subject><subject>Autoantibodies</subject><subject>chronic inflammatory demyelinating polyradiculoneuropathy</subject><subject>Contactin</subject><subject>contactin‐1</subject><subject>contactin‐associated protein 1</subject><subject>Demyelination</subject><subject>Guillain-Barre syndrome</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G4</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>neurofascin 155</subject><subject>Proteins</subject><subject>Steroid hormones</subject><subject>Tremor</subject><issn>1759-1961</issn><issn>1759-1961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc9KxDAQxosoKOrFJwh4E3Zt0nTbHGVZ_8CiFz2X2WS6m6VNapKivfkIPoLgm_goPolZV8GTc5gZht83M_AlyQlNxzTGuUSTjSkrsnwnOaBFLkZUTOjun34_OfZ-ncbIypIX_CB5v-iDBRP0wiqNnsAStPGBSGsCyKDN58sreG-lhoCKdM4G1ObjjRIwKlJt1-Bz1NmadODAWIVR4TuUutbyl_dEGyJXzpo406ZuoG0hWDcQhe2AjTYQTy1JZ5vBgdKyb6zB3tkOwmo4SvZqaDwe_9TD5OFydj-9Hs3vrm6mF_ORzNJJPioAGEOWFwoEV0JSvpClSieCLrCUWc35QtQxK5mylGZUSVWzHEEoLgSjKjtMTrd749ePPfpQrW3vTDxZsZLmfMI4LyJ1tqWks947rKvO6RbcUNG02vhQbXyovn2IMN3CT7rB4R-yms5us63mC5R1kqM</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Koga, Michiaki</creator><creator>Maeda, Toshihiko</creator><creator>Shimizu, Fumitaka</creator><creator>Kanda, Takashi</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0003-4163-2939</orcidid><orcidid>https://orcid.org/0000-0002-1356-955X</orcidid><orcidid>https://orcid.org/0000-0003-1049-4924</orcidid></search><sort><creationdate>202305</creationdate><title>Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy</title><author>Koga, Michiaki ; Maeda, Toshihiko ; Shimizu, Fumitaka ; Kanda, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3065-7aa22e257da94d9c14bc8d0691be8c3f44b9ff44dc020131dcdf25ea9d49921d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Ataxia</topic><topic>Autoantibodies</topic><topic>chronic inflammatory demyelinating polyradiculoneuropathy</topic><topic>Contactin</topic><topic>contactin‐1</topic><topic>contactin‐associated protein 1</topic><topic>Demyelination</topic><topic>Guillain-Barre syndrome</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G4</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>neurofascin 155</topic><topic>Proteins</topic><topic>Steroid hormones</topic><topic>Tremor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koga, Michiaki</creatorcontrib><creatorcontrib>Maeda, Toshihiko</creatorcontrib><creatorcontrib>Shimizu, Fumitaka</creatorcontrib><creatorcontrib>Kanda, Takashi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Clinical &amp; experimental neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koga, Michiaki</au><au>Maeda, Toshihiko</au><au>Shimizu, Fumitaka</au><au>Kanda, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy</atitle><jtitle>Clinical &amp; experimental neuroimmunology</jtitle><date>2023-05</date><risdate>2023</risdate><volume>14</volume><issue>2</issue><spage>116</spage><epage>121</epage><pages>116-121</pages><issn>1759-1961</issn><eissn>1759-1961</eissn><abstract>Objective To investigate the frequency of serum autoantibodies targeting contactin‐associated protein 1 (Caspr1) and its complexes with other paranode antigens, contactin‐1 (CNTN1) and neurofascin 155 (NF155), in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sera from 26 CIDP patients, 35 patients with Guillain–Barré syndrome, and 31 healthy individuals participated. Paranodal immunoglobulin G antibodies were quantified using enzyme‐linked immunosorbent assays with commercially available recombinant proteins as antigens. Results Anti‐Caspr1 antibodies were present in one participant (case 1, 3.8%) of CIDP, and negative in all Guillain–Barré syndrome patients and healthy participant. Case 1 was a man who developed subacute distal limb‐predominant muscle weakness and sensory ataxia with postural hand tremor at 69 years‐of‐age, and therapeutic benefit of intravenous immunoglobulin and oral steroids was inadequate. The detected anti‐Caspr1 antibodies predominantly belonged to the immunoglobulin G4 subclass, and the addition of CNTN1 to Caspr1 as an antigen increased antibody reactivity, although the increase was just 20–30% at most. The presence of autoantibodies against paranode protein complexes, including Caspr1/CNTN1, Caspr1/NF155 and Caspr1/CNTN1/NF155, was confirmed in several CIDP patients, although they also had anti‐Caspr1 or anti‐NF155 antibodies; thus, in our cohort, there were no patients with autoantibodies that specifically recognized paranode protein complexes. Conclusions This is the first confirmed Japanese case of anti‐Caspr1 antibody‐positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. The first Japanese case of anti‐contactin‐associated protein 1 antibody‐positive chronic inflammatory demyelinating polyradiculoneuropathy showed similar clinical pictures to cases reported from Western countries, including enlargement of the nerve roots with gadolinium contrast effect.</abstract><cop>Ube</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/cen3.12735</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4163-2939</orcidid><orcidid>https://orcid.org/0000-0002-1356-955X</orcidid><orcidid>https://orcid.org/0000-0003-1049-4924</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1759-1961
ispartof Clinical & experimental neuroimmunology, 2023-05, Vol.14 (2), p.116-121
issn 1759-1961
1759-1961
language eng
recordid cdi_proquest_journals_2815462447
source Wiley Online Library All Journals
subjects Antibodies
Antigens
Ataxia
Autoantibodies
chronic inflammatory demyelinating polyradiculoneuropathy
Contactin
contactin‐1
contactin‐associated protein 1
Demyelination
Guillain-Barre syndrome
Immunoglobulin G
Immunoglobulin G4
Immunoglobulins
Inflammation
neurofascin 155
Proteins
Steroid hormones
Tremor
title Autoantibodies against contactin‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A55%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoantibodies%20against%20contactin%E2%80%90associated%20protein%C2%A01%20and%20complexes%20of%20paranode%E2%80%90specific%20proteins%20in%20chronic%20inflammatory%20demyelinating%20polyradiculoneuropathy&rft.jtitle=Clinical%20&%20experimental%20neuroimmunology&rft.au=Koga,%20Michiaki&rft.date=2023-05&rft.volume=14&rft.issue=2&rft.spage=116&rft.epage=121&rft.pages=116-121&rft.issn=1759-1961&rft.eissn=1759-1961&rft_id=info:doi/10.1111/cen3.12735&rft_dat=%3Cproquest_cross%3E2815462447%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2815462447&rft_id=info:pmid/&rfr_iscdi=true